Keywords: gw, files, relenza, approval, japan, glaxo, wellcome

GW files for Relenza approval in Japan

Article | 10 August 1999

Print This

Glaxo Wellcome has filed for approval to market its new inhaledneuraminidase inhibitor Relenza (zanamivir) in Japan for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in